St. John's College, Oxford
St Giles, Oxford, Oxfordshire, OX1 3JP, United Kingdom
Overview
St John's College - Oxford is an educational institution that offers undergraduate and graduate programs. Their undergraduates are taught by tutors and lecturers who are specialists in their respective disciplines. They are encouraged to think for themselves and to challenge themselves academically. St John's College - Oxford admits about 90 graduate students each year and has a graduate community of roughly 250 students total. St John's College - Oxford was founded in 1555 by Sir Thomas White.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Optellum
Participated · Seed · Jul 2019
Optellum develops Virtual Nodule Clinic, an AI-enabled software platform that helps physicians identify and track at-risk lung nodules and diagnose lung cancer early. The platform has attained FDA clearance, CE-MDR in the EU, and UKCA in the UK. The company intends to use its Series A funds to scale its base, operations, and commercial launches in the UK and USA, accelerate research and development, and expand the platform into personalized therapy decisions by integrating imaging data with molecular data, robotics, and liquid biopsies. Optellum has strategic collaborations with GE Healthcare and the Lung Cancer Initiative at Johnson & Johnson to accelerate clinical deployments. Its solution is being used to predict at-risk lung nodules in a multi-center study with NHS Trusts in the UK. The company is led by CEO Jason Pesterfield and founder Tara Bishop, MD, and maintains a U.S. office at the Texas Medical Center in Houston. Optellum develops the world's first AI clinical decision‑support software applied to CT scans to help clinicians detect, diagnose and manage suspicious lung lesions at earlier stages. The platform aims to enable earlier treatment and reduce over‑diagnosis and unnecessary invasive procedures; the article cites that 85% of lung cancer patients could survive more than five years if treated at stage 1A. Optellum's predictive machine‑learning algorithms were validated against the largest real‑world dataset, including CT scans, clinical data and tissue analyses from dozens of hospitals in the US and Europe. The solution is described as the first predictive machine‑learning approach applied to lung cancer and is being validated in an ongoing prospective multi‑centre trial led by co‑authors of the UK lung cancer management guidelines. The company says its vision is to follow the patient journey and enable faster, more optimal management decisions across the lung cancer care continuum and in other lung diseases including COPD, interstitial lung disease and pulmonary hypertension. Optellum is Oxford‑based and recently completed a seed follow‑on financing of £3.25m.
Team
No current team members are available.